T-ALL Follow-Up Flow Panel
Also known as: T-Cell Acute Lymphoblastic Leukemia/Lymphoma Follow-Up Panel
Use
The T-ALL Follow-Up Flow Panel is utilized to monitor minimal residual disease in patients undergoing treatment for T-cell Acute Lymphoblastic Leukemia (T-ALL). It provides crucial information on the presence and level of neoplastic cells, helping guide treatment decisions post-therapy. This panel includes a comprehensive assessment of 16 markers to evaluate disease status.
Special Instructions
Globally available as both a complete package and tech-only. Clinical history including time post-treatment should be provided. It is strongly recommended to have prior immunophenotyping at NeoGenomics with Standard or Extended Flow Panel.
Limitations
The test may be limited by the sample quality and volume. Samples must be received within the specified timeframe to maintain cell viability. Analytical sensitivity can vary based on marker expression levels and cell population heterogeneity. Accurate interpretation requires consideration of the patient's clinical history and prior immunophenotyping data.
New York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
Result Turnaround Time
1 day
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
1-2 mL
Minimum Volume
Not provided
Container
EDTA or sodium heparin; lithium heparin or ACD not acceptable.
Collection Instructions
Provide recent CBC report.
Storage Instructions
Refrigerate specimen. Do not freeze. Use cold pack for transport, ensuring not in direct contact with specimen.
Causes for Rejection
ACD tube or extended time from collection.
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 72 hours |